Are magic mushrooms dangerous?

From WikiPsilocybin, the free psilocybin encyclopedia — a harm-reduction article

This article covers the risks, side effects, and safety of psilocybin mushrooms ("shrooms"). For the compound itself, see Psilocybin. For dependence and abuse potential, see Are shrooms addictive?

Magic mushrooms are among the least physically dangerous recreational drugs studied, but they are not risk-free. The key dangers are psychological rather than toxicological: frightening or destabilising experiences, accidents while impaired, and the triggering of psychosis in people with a personal or family history of psychotic disorders. A separate and under-appreciated danger is eating the wrong mushroom, since several deadly species resemble psilocybin-containing ones.^[4][6]

In the 2010 Lancet multicriteria analysis led by David Nutt, psilocybin mushrooms scored lowest on combined harm to users and to others out of 20 drugs, below cannabis, alcohol, tobacco, and every other substance assessed.^[1] A 2011 review commissioned for Dutch drug policy reached a similar conclusion, describing the physical and psychological harm potential of magic mushrooms as low.^[2] This article lays out what the evidence actually shows, where the real risks lie, and how to reduce them.

The short answer

How dangerous are shrooms? Physically, very little. Psilocybin has no known organ toxicity at the doses people take, does not depress breathing, and the estimated dose needed to kill a person is on the order of a thousand times a typical effective dose.^[3] No reliable case of a fatal overdose from psilocybin mushrooms alone has been documented in a healthy adult; the handful of deaths in the literature involved toxic look-alike species, pre-existing heart disease, other drugs, or accidents such as falls and drowning while intoxicated.^[4][5]

Psychologically, the picture is more nuanced. In the largest survey of difficult psilocybin experiences, 39% of nearly 2,000 respondents rated their worst "bad trip" among the five most challenging experiences of their lives, 11% said they put themselves or others at risk of physical harm during it, and 7.6% sought treatment for lasting psychological symptoms afterward.^[7] Most of those episodes occurred without a sober sitter, in unplanned settings, or at high doses.

Side effects

Magic mushroom side effects fall into three groups: physical, perceptual, and psychological. Acute effects begin 20–40 minutes after ingestion, peak around 60–90 minutes, and resolve within roughly six hours.^[8]

Type	Common effects	Notes
Physical	Nausea, vomiting (usually early), pupil dilation, modest rises in heart rate and blood pressure, sweating, chills, muscle weakness, poor coordination, yawning	In controlled trials, blood pressure and heart rate rise moderately and return to baseline within hours; nausea is the most frequent complaint.[8][9]
Perceptual	Visual distortion and patterning, altered sense of time, synaesthesia, sound and colour intensification	Dose-dependent; expected effects, not adverse events per se.
Psychological	Euphoria, awe, laughter, emotional openness; also anxiety, fear, paranoia, confusion, feeling of losing control	In a Johns Hopkins high-dose study, about a third of volunteers experienced significant fear or anxiety at some point during the session, even with careful preparation.[10]
Next-day	Fatigue, headache, low mood or, conversely, elevated mood ("afterglow")	Headache after psilocybin is dose-related, begins after the acute effects, and resolves within a day or two.[11]

A pooled analysis of 110 healthy volunteers across eight Swiss laboratory studies found that psilocybin at doses up to 0.315 mg/kg produced no persisting perceptual, psychological, or physical harm in any participant during follow-up.^[9]

Bad trips and psychological risk

A "bad trip" is an acute episode of intense anxiety, panic, paranoia, dysphoria, or disorientation during the drug's effects. It is the most common serious adverse experience associated with magic mushrooms and the usual reason people present to emergency departments.^[12] Bad trips are strongly tied to dose, mindset ("set"), and environment ("setting").^[13]

Carbonaro and colleagues' 2016 survey of 1,993 people who had experienced a difficult psilocybin trip found:^[7]

• The median dose in the worst experience was about 4 grams of dried mushrooms, roughly a high dose.
• 11% put themselves or others at risk of physical harm; 2.6% acted aggressively or violently; 2.7% sought medical help during the episode.
• Three respondents with pre-existing anxiety, depression, or suicidal ideation attempted suicide during the experience.
• 7.6% sought treatment for enduring psychological symptoms afterward.
• Despite this, 84% said they benefited from the experience, and difficulty was positively associated with reported personal meaning.

Being alone, being in an unfamiliar or public place, and taking a larger dose than intended all made harm more likely. These are the variables harm-reduction practice targets.

Mental health, psychosis, and HPPD

The most serious psychiatric risk is precipitating a prolonged psychotic episode in someone predisposed to psychotic disorders such as schizophrenia or bipolar I disorder. Clinical trials exclude such participants, so prospective data on this group are lacking; the exclusion itself reflects a consensus that the risk is real.^[13][14] Case reports describe psychosis, mania, and prolonged mood destabilisation following mushroom use, usually in people with personal or family histories of these conditions.^[14]

For the general population, large epidemiological studies have not found that psychedelic use raises the rate of mental-health problems. An analysis of 130,152 US adults in the National Survey on Drug Use and Health found no association between lifetime psychedelic use (including psilocybin) and serious psychological distress, mental-health treatment, or symptoms of panic, depression, anxiety, or psychosis; some associations ran in the protective direction.^[15] A follow-up analysis of 190,000 adults similarly found lower rates of past-month psychological distress and suicidality among classic-psychedelic users.^[16] These are correlational findings and cannot rule out risk for vulnerable subgroups.

Hallucinogen persisting perception disorder (HPPD), in which visual disturbances such as trails, halos, or visual snow persist for weeks to years, is a recognised DSM-5 diagnosis. It appears to be rare, is more often associated with LSD than with psilocybin, and did not occur in any participant across the modern controlled-trial literature, though population surveys suggest transient "flashback" phenomena are not uncommon and usually fade.^[17]

Can you overdose? Toxicity and poisoning

A magic mushroom "overdose" in the sense of a life-threatening toxic dose is not a practical concern. Robert Gable's comparative analysis estimated psilocybin's lethal dose in humans at roughly 1,000 times the effective dose, versus about 10 for alcohol and 6 for intravenous heroin.^[3] Animal studies place the median lethal dose of psilocybin at around 280 mg/kg in rats, hundreds of times the human active dose per kilogram.^[2] Because a dried mushroom contains roughly 0.5–1% psilocybin by weight, reaching a physically lethal amount by eating mushrooms is considered effectively impossible.^[2][4]

What people usually mean by "overdose" is taking far more than intended, which produces an overwhelming, frightening experience rather than organ damage. Symptoms of a very high dose include severe confusion, inability to communicate, agitation, panic, vomiting, and in rare cases seizures or high temperature, the latter most often reported when other substances were involved.^[12]

Poisoning by misidentified mushrooms

The genuinely lethal scenario involving "magic mushrooms" is eating a toxic species by mistake. Deadly Amanita and Galerina species, which contain amatoxins that destroy the liver, can grow in the same habitats and superficially resemble some Psilocybe species. Amatoxin poisoning is deceptive: gastrointestinal symptoms appear 6–24 hours after ingestion, seem to improve, and then liver failure develops over the following days.^[6] Any mushroom eaten from the wild that produces delayed vomiting and diarrhoea many hours later is a medical emergency, not a bad trip.

Psilocybin exposures reported to US poison centers rose sharply in the early 2020s, with a more-than-threefold increase among adolescents between 2018 and 2022, and roughly three-quarters of adolescent cases required medical attention.^[18] Most reported effects were hallucinations, agitation, and rapid heart rate; serious outcomes were uncommon.

Rare severe cases

A small number of case reports describe serious physical harm after mushroom use, including rhabdomyolysis with acute kidney injury, and a fatal cardiac arrest in a heart-transplant recipient whose transplanted heart could not respond normally to the drug's autonomic effects.^[5] Kidney and heart complications are more strongly associated with other mushroom genera (for example Cortinarius) and with co-ingested drugs than with psilocybin itself.^[4] They are documented here because they exist, not because they are typical.

Emergency symptoms

A person who is frightened, confused, crying, or convinced something is wrong but who is physically stable does not usually need an ambulance. What helps is a calm companion, a quiet safe space, reassurance that the effects are temporary and will pass within a few hours, and avoiding restraint or argument.^[19] If in doubt, call Poison Control; the service is free, confidential, and can advise on whether hospital care is needed.

Drug interactions

• Lithium — the most important documented interaction. In an analysis of 62 online reports of classic psychedelics combined with lithium, 47% involved seizures and 18% required emergency medical attention; lamotrigine showed no such pattern.^[20] Psilocybin should not be combined with lithium.
• SSRIs and SNRIs — antidepressants tend to blunt psilocybin's subjective effects rather than produce dangerous ones; serotonin syndrome from psilocybin alone is not documented but is a theoretical concern when combined with MAOIs or tramadol.^[21]
• MAOIs — monoamine oxidase inhibitors can intensify and prolong psilocin's effects unpredictably.^[21]
• Alcohol and cannabis — both increase the likelihood of nausea, confusion, and a difficult experience; alcohol adds injury risk.^[12]
• Stimulants — combining with amphetamines, MDMA, or cocaine raises heart rate and blood pressure further and increases anxiety and hyperthermia risk.

Effects on the brain

Psilocybin's effects on the brain are the subject of the site's main article; here the question is whether those effects are harmful. Psilocin acts primarily at serotonin 5-HT_2A receptors, transiently reducing default-mode-network integrity and increasing communication between brain networks that are normally segregated.^[22] A 2024 Nature study found that a single high dose desynchronised cortical networks for the duration of the drug's effects, with a smaller change in the hippocampal-default-mode connection persisting for weeks.^[23]

These changes are considered the basis of both the acute experience and the reported therapeutic effects, and no study has found evidence that psilocybin damages neurons. Animal and cell studies suggest the opposite: increased dendritic spine density and expression of neuroplasticity-related genes.^[24] Whether these plasticity effects could be harmful in a developing brain is unknown; there are almost no controlled data in adolescents, which is one reason youth use is discouraged.^[18]

Who should avoid psilocybin

Based on the exclusion criteria used in clinical trials and published safety guidelines:^[13]

• People with a personal or first-degree family history of schizophrenia, schizoaffective disorder, bipolar I disorder, or other psychotic conditions.
• People taking lithium, or those on MAOIs.
• People with uncontrolled hypertension, recent stroke or heart attack, serious arrhythmia, or other significant cardiovascular disease, because of the transient rise in blood pressure and heart rate.
• People who are pregnant or breastfeeding (no safety data).
• Adolescents and children.
• Anyone currently in acute crisis, severely intoxicated, or without a safe place and person to be with.

Harm reduction

The following measures address the documented sources of harm. They are drawn from clinical safety guidelines^[13], the survey literature on difficult experiences^[7], and harm-reduction organisations such as the Zendo Project and DanceSafe.^[19]

1. Know what you have. Never eat foraged mushrooms unless a competent identifier has confirmed the species. Misidentification is the single scenario most likely to be fatal.
2. Screen yourself. Review the contraindications above honestly, including family history and current medications.
3. Start low. Potency varies severalfold between species and even between batches. A first dose of 1 gram or less of dried Psilocybe cubensis gives a sense of the effect; the survey median for worst experiences was around 4 grams.
4. Have a sober sitter. A trusted, sober person who can reassure, redirect, and call for help if needed is the single most effective safeguard against harm during a bad trip.
5. Choose the setting. Private, familiar, safe from traffic, water, heights, and heavy machinery. Do not drive. Plan to stay put for six hours.
6. Do not mix. Especially not with lithium, alcohol, or stimulants.
7. Prepare for difficulty. Anxiety and fear are common and pass. Breathing slowly, changing rooms, changing music, and being reminded that the drug will wear off are the standard supports. "Trust, let go, be open" is the phrase used in Johns Hopkins sessions.^[10]
8. Know when to call. See the emergency symptoms above. Poison Control does not involve law enforcement.
9. Integrate afterward. Talking through the experience with a trusted person or therapist reduces the chance of lingering distress.

Risks versus benefits

Psilocybin risks and benefits are increasingly being weighed formally. On the benefit side, randomised trials have reported large reductions in depression,^[25] and reductions in heavy drinking in alcohol use disorder,^[26] typically after one or two supervised doses. On the risk side, the same trials report transient anxiety, headache, nausea, and blood-pressure elevation, and very occasional prolonged distress. In supervised settings with medical screening, no trial has reported a death, a persistent psychosis, or a case of HPPD.^[9][25]

Those results do not transfer directly to unsupervised use, where the screening, dosing accuracy, and support that produce the safety record are absent. The gap between clinical safety and real-world risk is precisely what harm reduction attempts to close.

See also

References